Johnson & Johnson Covid vaccine shipments halted in US after factory blunder destroys 15 million doses
Company spokeswoman says error was discovered before the identified batch of vaccines finished the production process
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Future Johnson & Johnson vaccine shipments have been halted in the United States after a human error mix up in a new manufacturing plant destroyed 15 million doses and raised questions over quality control, according to The New York Times.
Regulators delayed authorisation of a new vaccine production line in Baltimore after workers accidentally conflated the ingredients of two different vaccines several weeks ago, the outlet reported.
The plant is said to be a manufacturing partner for both the Johnson & Johnson vaccine and the AstraZeneca vaccine.
While current doses of the Johnson & Johnson vaccine produced in the Netherlands are not affected, tens of millions of future doses scheduled to be delivered within the next month were to have come from the plant in Maryland, according to the Times.
The Food and Drug Administration is investigating the mix-up, attributed to human error, causing a delay to the authorisation of the plant’s production line. Johnson & Johnson, meanwhile, was reportedly taking steps to increase its control over the plant, run by Emergent BioSolutions, to avoid further lapses in quality.
Read more:
A Johnson & Johnson spokeswoman said in a statement that the issue was identified by its representatives at the factory and addressed with both its manufacturing partner and the FDA.
“This quality control process identified one batch of drug substance that did not meet quality standards at Emergent BioSolutions, a site not yet authorised to manufacture drug substance for our Covid-19 vaccine,” the statement said.
“This batch was never advanced to the filling and finishing stages of our manufacturing process.”
The spokeswoman said they were sending additional manufacturing and technical operation experts to the site, while continuing to work with the FDA on seeking emergency use authorisation for the facility.
The company signed a five-year deal with Maryland-based manufacturer Emergent to produce the Covid-19 vaccine.
An FDA spokesperson confirmed to The Independent in an email statement that they’re “aware of the situation” but would not comment further. Emergent BioSolutions did not immediately respond to a request for comment.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments